8
Aug
2018
The Antibiotic Opportunity? Spero’s Ankit Mahadevia on The Long Run Podcast
Today’s guest on The Long Run podcast is Ankit Mahadevia. Mahadevia is the CEO of Cambridge, Mass.-based Spero Therapeutics. It’s an antibiotic developer. Specifically, it’s focused on new strategies for fighting gram-negative bacterial infections that are increasingly resistant to our existing set of antibiotics. Despite persistent warnings from global health authorities about the rise of multi-drug resistant bugs, and the...Read More 
Share:
7
Aug
2018
5AM, NEA Lead $50M Bet on Akouos, Crafting Gene Therapy for the Ear
This content is available for subscribers of Timmerman Report. Subscribe Now Sign in to your account.
Share:
3
Aug
2018
BeiGene’s Cash Haul, Illumina’s Big Q2, & Startups Keep Hiring Pharma Vets
This content is available for subscribers of Timmerman Report. Subscribe Now Sign in to your account.
Share:
31
Jul
2018
Verana, Backed by GV & Brook Byers, Grabs $30M to Squeeze Meaning Out of EMRs
This content is available for subscribers of Timmerman Report. Subscribe Now Sign in to your account.
Share:
27
Jul
2018
An Alzheimer’s Hope-Fest, GSK Cozies Up to 23andMe, & A Gilead Legend Steps Aside
This content is available for subscribers of Timmerman Report. Subscribe Now Sign in to your account.
Share:
26
Jul
2018
Betting on Biotech IPOs? What If You Buy the Third Rock and ARCH Portfolios?
This content is available for subscribers of Timmerman Report. Subscribe Now Sign in to your account.
Share:
25
Jul
2018
Alector, Staying Private for Now, Pulls in $133M for Alzheimer’s R&D
This content is available for subscribers of Timmerman Report. Subscribe Now Sign in to your account.
Share:
25
Jul
2018
Finding the ‘Middle Market’ of Biotech VC: Chris Garabedian on The Long Run Podcast
Today’s guest on The Long Run podcast is Chris Garabedian. Garabedian is best known for his controversial stint as CEO of Cambridge, Mass.-based Sarepta Therapeutics, the developer of treatments for Duchenne Muscular Dystrophy. Whatever you may think of his tenure there — and the FDA’s decision to approve eteplirsen on a slim reed of clinical trial evidence – there is...Read More
Share:
20
Jul
2018
Novartis, Merck Back Off on Prices, Rubius Leads IPO Charge, CRISPR Stocks Rattled
This content is available for subscribers of Timmerman Report. Subscribe Now Sign in to your account.
Share:
17
Jul
2018
Nine Observations on Leadership and Teamwork from Mt. Everest
Most of you have heard by now that I reached the summit of Mt. Everest, the highest mountain in the world, on May 22. Not only was this a dream come true, it was the culmination of my charity fundraising campaign, the Everest Climb to Fight Cancer. It fetched $339,000 for cancer research at the Fred Hutch, a leading center...Read More
Share:
17
Jul
2018
HotSpot Therapeutics Raises $45M to Follow in Nimbus’ Footsteps, Creating Allosteric Binders
This content is available for subscribers of Timmerman Report. Subscribe Now Sign in to your account.
Share:
13
Jul
2018
Novartis Bails on Antibiotics, Acceleron Goes 2-for-2, & Grail CEO Assembles Her Team
This content is available for subscribers of Timmerman Report. Subscribe Now Sign in to your account.
Share:
10
Jul
2018
Scientist, Executive, Teacher: Vicki Sato on The Long Run Podcast
Vicki Sato is the latest guest on The Long Run podcast. Regular listeners may recall I invited Vicki on the show back in March. We had a great conversation, or so I thought. Turns out the audio recording quality was terrible. It was a technical glitch. My fault. I’m sorry you weren’t able to hear her. Fortunately, Vicki was gracious...Read More
Share:
6
Jul
2018
Biogen Hits on Alzheimer’s Study, EpiPen Rival Gets a Lift, & Bayer Doubles Down on Broad
This content is available for subscribers of Timmerman Report. Subscribe Now Sign in to your account.
Share:
29
Jun
2018
Amazon’s Chess Move and the Pre-Holiday IPO Wave Continues
This content is available for subscribers of Timmerman Report. Subscribe Now Sign in to your account.
Share:
28
Jun
2018
How Are Biotech VC Funds Performing? See Data From Five State Pension Funds
This content is available for subscribers of Timmerman Report. Subscribe Now Sign in to your account.
Share:
27
Jun
2018
How Are Biotech’s VCs Performing? Not As Well As You May Think
This content is available for subscribers of Timmerman Report. Subscribe Now Sign in to your account.
Share:
22
Jun
2018
Sarepta’s Stunner, Summer IPO Wave, and a White House Plan to Clip Wings at FDA
This content is available for subscribers of Timmerman Report. Subscribe Now Sign in to your account.
Share:
21
Jun
2018
Impact in More Ways Than One: Tony Coles on The Long Run Podcast
I’m happy to introduce the latest guest on The Long Run podcast — Tony Coles. He is the co-founder and CEO of Yumanity Therapeutics, a Cambridge, Mass.-based company doing drug discovery work against neurodegenerative diseases. That means Alzheimer’s disease, Parkinson’s disease and amyotrophic lateral sclerosis (Lou Gehrig’s disease). This is a fascinating time to be focused on neurodegenerative diseases. The...Read More
Share:
19
Jun
2018
So You Want To Get Into Biotech…Part 2: Banana Peel? What Banana Peel?
Although learning more about the many ways in which one can get an interview and first job in biotech and pharma helps, that’s not where it ends. Everyone I know in biopharma has stories of dealing with co-workers who just didn’t get what the industry is about, in the interview or during those pivotal first years. This despite a system...Read More
Share:
